Brain Res 546, 282-286, (1991). Earley, B., Burke, M., Leonard, B. E., Gouret, C. J., & Junien, J. L. View abstract in PubMed Post navigationPreviousPrevious post:N-methyl-Daspartate- induced neuronal activation is selectively modulated by sigma receptors.NextNext post:Overexpression of sigma receptors in nonneural human tumors.Related PostsAnavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)August 26, 2021Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s DiseaseJuly 29, 2021Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease DementiaJune 28, 2021Anavex Life Sciences Announces Closing of $50 Million Registered Direct OfferingJune 24, 2021
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)August 26, 2021
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s DiseaseJuly 29, 2021
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease DementiaJune 28, 2021
